MLYS
NASDAQ · Biotechnology
Mineralys Therapeutics Inc
$24.07
+0.79 (+3.39%)
Financial Highlights (FY 2025)
Revenue
422.84M
Net Income
48.98M
Gross Margin
63.8%
Profit Margin
11.6%
Rev Growth
+5.2%
D/E Ratio
0.29
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 63.8% | 63.8% | 63.8% |
| Operating Margin | 13.2% | 12.0% | 12.4% |
| Profit Margin | 11.6% | 11.3% | 9.9% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 422.84M | 383.53M | 332.94M |
| Gross Profit | 269.98M | 244.88M | 212.58M |
| Operating Income | 55.98M | 45.89M | 41.38M |
| Net Income | 48.98M | 43.51M | 33.06M |
| Gross Margin | 63.8% | 63.8% | 63.8% |
| Operating Margin | 13.2% | 12.0% | 12.4% |
| Profit Margin | 11.6% | 11.3% | 9.9% |
| Rev Growth | +5.2% | +16.0% | +2.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 239.29M | 200.90M | 213.61M |
| Total Equity | 830.16M | 707.42M | 761.86M |
| D/E Ratio | 0.29 | 0.28 | 0.28 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 63.20M | 67.45M | 57.44M |
| Free Cash Flow | 26.85M | 26.46M | 31.26M |